Bp5250 inhibits vascular endothelial growth factor-induced angiogenesis and HIF-1α expression on endothelial cells

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 385, Issue 1, 2012, Pages 39-49

  Lin, Kuan Ting ^a   Lien, Jin Cherng ^b   Chung, Ching Hu ^c   Kuo, Sheng Chu ^b   Huang, Tur Fu ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c TZU CHI UNIVERSITY   (Taiwan)

Author keywords

Angiogenesis; Endothelial cell; Hypoxia inducible factor 1 ; Vascular endothelial growth factor

Indexed keywords

ANGIOGENESIS INHIBITOR; BP 5250; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE B; PROTEIN KINASE P60; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; NONHUMAN; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS INHIBITORS; ANIMALS; ANOXIA; AORTA; APOPTOSIS; CELL MOVEMENT; CELL PROLIFERATION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PHYSIOLOGIC; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84857034739     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-011-0690-2     Document Type: Article

References (47)

1. H Abedi I Zachary 1997 Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells J Biol Chem 272 24 15442 15451 9182576 10.1074/jbc.272.24.15442 1:CAS:528:DyaK2sXjvFOmsLo%3D (Pubitemid 27255570)
2. DM Aebersold P Burri KT Beer J Laissue V Djonov RH Greiner, et al. 2001 Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer Cancer Res 61 7 2911 2916 11306467 1:CAS:528:DC%2BD3MXivFGqsr8%3D (Pubitemid 32691934)
3. 2 availability on human cancer Nat Rev Cancer 8 12 967 975 18987634 10.1038/nrc2540 1:CAS:528:DC%2BD1cXhsVWhu7fO
4. F Bondavalli O Bruno A Ranise P Schenone C Losasso L Stella, et al. 1990 3,5-Diphenyl-1H-pyrazole derivatives. VI-Esters and 2-dialkylaminoethyl ethers of 1(2-hydroxy-2-phenylethyl)-3,5-diphenyl-1H-pyrazole and N, N-disubstituted 1-(2-amino-2-phenylethyl)-3,5-diphenyl-1H-pyrazoles with depressant and platelet antiaggregating activities Farmaco 45 5 511 526 2222723 1:CAS:528: DyaK3MXotFKrtw%3D%3D (Pubitemid 20311804)
5. BA Bryan PA D'Amore 2007 What tangled webs they weave: Rho-GTPase control of angiogenesis Cell Mol Life Sci 64 16 2053 2065 17530172 10.1007/s00018-007- 7008-z 1:CAS:528:DC%2BD2sXhtVaisb7J (Pubitemid 350092415)
6. CP Carden JM Larkin MA Rosenthal 2008 What is the risk of intracranial bleeding during anti-VEGF therapy? Neuro Oncol 10 4 624 630 18539884 10.1215/15228517-2008-010
7. P Carmeliet RK Jain 2000 Angiogenesis in cancer and other diseases Nature 407 6801 249 257 11001068 10.1038/35025220 1:CAS:528:DC%2BD3cXmvVSls74%3D
8. AS Chung J Lee N Ferrara 2010 Targeting the tumour vasculature: insights from physiological angiogenesis Nat Rev Cancer 10 7 505 514 20574450 10.1038/nrc2868 1:CAS:528:DC%2BC3cXnvVSgsro%3D
9. KM Cook WD Figg 2010 Angiogenesis inhibitors: current strategies and future prospects CA Cancer J Clin 60 4 222 243 20554717 10.3322/caac.20075
10. GE Davis KJ Bayless A Mavila 2002 Molecular basis of endothelial cell morphogenesis in three-dimensional extracellular matrices Anat Rec 268 3 252 275 12382323 10.1002/ar.10159 1:CAS:528:DC%2BD38Xosl2qs7o%3D (Pubitemid 35246845)
11. F Dayan NM Mazure MC Brahimi-Horn J Pouyssegur 2008 A dialogue between the hypoxia-inducible factor and the tumor microenvironment Cancer Microenviron 1 1 53 68 19308685 10.1007/s12307-008-0006-3
12. J Fang Q Zhou LZ Liu C Xia X Hu X Shi, et al. 2007 Apigenin inhibits tumor angiogenesis through decreasing HIF-1alpha and VEGF expression Carcinogenesis 28 4 858 864 17071632 10.1093/carcin/bgl205 1:CAS:528: DC%2BD2sXjslOnsbk%3D (Pubitemid 46523341)
13. AM Farag AS Mayhoub SE Barakat AH Bayomi 2008 Regioselective synthesis and antitumor screening of some novel N-phenylpyrazole derivatives Bioorg Med Chem 16 2 881 889 17962022 10.1016/j.bmc.2007.10.015 1:CAS:528: DC%2BD1cXhsF2jsr8%3D (Pubitemid 351175638)
14. J Folkman 1971 Tumor angiogenesis: therapeutic implications N Engl J Med 285 21 1182 1186 4938153 10.1056/NEJM197111182852108 1:STN:280: DyaE38%2FgvVCqsQ%3D%3D
15. J Folkman 1995 Clinical applications of research on angiogenesis N Engl J Med 333 26 1757 1763 7491141 10.1056/NEJM199512283332608 1:STN:280: DyaK28%2Fpt1ejuw%3D%3D (Pubitemid 26009687)
16. J Folkman 2007 Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6 4 273 286 17396134 10.1038/nrd2115 1:CAS:528: DC%2BD2sXjs1SisL4%3D (Pubitemid 46505878)
17. LJ Gay B Felding-Habermann 2011 Contribution of platelets to tumour metastasis Nat Rev Cancer 11 2 123 134 21258396 10.1038/nrc3004 1:CAS:528:DC%2BC3MXps1aisQ%3D%3D
18. MJ Genin C Biles BJ Keiser SM Poppe SM Swaney WG Tarpley, et al. 2000 Novel 1,5-diphenylpyrazole nonnucleoside HIV-1 reverse transcriptase inhibitors with enhanced activity versus the delavirdine-resistant P236L mutant: lead identification and SAR of 3- and 4-substituted derivatives J Med Chem 43 5 1034 1040 10715167 10.1021/jm990383f 1:CAS:528:DC%2BD3cXpsV2gsg%3D%3D (Pubitemid 30152308)
19. MS Gordon D Cunningham 2005 Managing patients treated with bevacizumab combination therapy Oncology 69 Suppl 3 25 33 16301833 10.1159/000088481 1:CAS:528:DC%2BD2MXht1aqsrbP (Pubitemid 41680950)
20. D Hanahan J Folkman 1996 Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis Cell 86 3 353 364 8756718 10.1016/S0092-8674(00)80108-7 1:CAS:528:DyaK28XltVSks7s%3D (Pubitemid 26272076)
21. T Hiraga S Kizaka-Kondoh K Hirota M Hiraoka T Yoneda 2007 Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer Cancer Res 67 9 4157 4163 17483326 10.1158/0008-5472.CAN-06-2355 1:CAS:528:DC%2BD2sXltVyrsrk%3D (Pubitemid 46815061)
22. YT Huang SL Pan JH Guh YL Chang FY Lee SC Kuo, et al. 2005 YC-1 suppresses constitutive nuclear factor-kappaB activation and induces apoptosis in human prostate cancer cells Mol Cancer Ther 4 10 1628 1635 16227413 10.1158/1535-7163.MCT-05-0090 1:CAS:528:DC%2BD2MXhtFWhtLnF (Pubitemid 41556446)
23. C Huang J Li L Song D Zhang Q Tong M Ding, et al. 2006 Black raspberry extracts inhibit benzo(a)pyrene diol-epoxide-induced activator protein 1 activation and VEGF transcription by targeting the phosphotidylinositol 3-kinase/Akt pathway Cancer Res 66 1 581 587 16397275 10.1158/0008-5472.CAN-05- 1951 1:CAS:528:DC%2BD28XhsFWkuw%3D%3D (Pubitemid 43166067)
24. AB Jaffe A Hall 2005 Rho GTPases: biochemistry and biology Annu Rev Cell Dev Biol 21 247 269 16212495 10.1146/annurev.cellbio.21.020604.150721 1:CAS:528:DC%2BD2MXhtlektbrI (Pubitemid 41740635)
25. EA Jaffe RL Nachman CG Becker CR Minick 1973 Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria J Clin Invest 52 11 2745 2756 4355998 10.1172/JCI107470 1:STN:280:DyaE2c%2FitFKgug%3D%3D
26. S Jain J Harris J Ware 2010 Platelets: linking hemostasis and cancer Arterioscler Thromb Vasc Biol 30 12 2362 2367 21071699 10.1161/ATVBAHA.110. 207514 1:CAS:528:DC%2BC3cXhsVCksb%2FN
27. BH Jiang LZ Liu 2008 AKT signaling in regulating angiogenesis Curr Cancer Drug Targets 8 1 19 26 18288940 10.2174/156800908783497122 1:CAS:528: DC%2BD1cXitF2ku7g%3D (Pubitemid 351237906)
28. Y Kubota HK Kleinman GR Martin TJ Lawley 1988 Role of laminin and basement membrane in the morphological differentiation of human endothelial cells into capillary-like structures J Cell Biol 107 4 1589 1598 3049626 10.1083/jcb.107.4.1589 1:CAS:528:DyaL1cXmtVyku7Y%3D
29. DI Leavesley MA Schwartz M Rosenfeld DA Cheresh 1993 Integrin beta 1- and beta 3-mediated endothelial cell migration is triggered through distinct signaling mechanisms J Cell Biol 121 1 163 170 7681432 10.1083/jcb.121.1.163 1:CAS:528:DyaK3sXhvVyltrc%3D (Pubitemid 23097372)
30. NB Leighl J Bennouna J Yi N Moore J Hambleton H Hurwitz 2011 Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study Br J Cancer 104 3 413 418 21245868 10.1038/sj.bjc.6606074 1:CAS:528:DC%2BC3MXhsVOrs7g%3D
31. SH Li DH Shin YS Chun MK Lee MS Kim JW Park 2008 A novel mode of action of YC-1 in HIF inhibition: stimulation of FIH-dependent p300 dissociation from HIF-1{alpha} Mol Cancer Ther 7 12 3729 3738 19074848 10.1158/1535-7163.MCT-08- 0074 1:CAS:528:DC%2BD1cXhsV2iurnK
32. YN Liu SL Pan CY Peng JH Guh DM Huang YL Chang, et al. 2006 YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole] inhibits neointima formation in balloon-injured rat carotid through suppression of expressions and activities of matrix metalloproteinases 2 and 9 J Pharmacol Exp Ther 316 1 35 41 16183705 10.1124/jpet.105.090563 1:CAS:528:DC%2BD28Xhslektg%3D%3D (Pubitemid 41832578)
33. P Mirshahi SK Toprak AM Faussat S Dubrulle JP Marie C Soria, et al. 2006 Malignant hematopoietic cells induce an increased expression of VEGFR-1 and VEGFR-3 on bone marrow endothelial cells via AKT and mTOR signalling pathways Biochem Biophys Res Commun 349 3 1003 1010 16959214 10.1016/j.bbrc.2006.08.132 1:CAS:528:DC%2BD28XpvFCqtLs%3D (Pubitemid 44399830)
34. R Munoz-Chapuli AR Quesada M Angel Medina 2004 Angiogenesis and signal transduction in endothelial cells Cell Mol Life Sci 61 17 2224 2243 15338053 10.1007/s00018-004-4070-7 1:CAS:528:DC%2BD2cXovVyhtbg%3D (Pubitemid 39280120)
35. RF Nicosia A Ottinetti 1990 Modulation of microvascular growth and morphogenesis by reconstituted basement membrane gel in three-dimensional cultures of rat aorta: a comparative study of angiogenesis in matrigel, collagen, fibrin, and plasma clot Vitro Cell Dev Biol 26 2 119 128 10.1007/BF02624102 1:STN:280:DyaK3c7os1Khsg%3D%3D (Pubitemid 20094385)
36. SL Pan JH Guh CY Peng SW Wang YL Chang FC Cheng, et al. 2005 YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole] inhibits endothelial cell functions induced by angiogenic factors in vitro and angiogenesis in vivo models J Pharmacol Exp Ther 314 1 35 42 15784655 10.1124/jpet.105.085126 1:CAS:528:DC%2BD2MXmtVejtLk%3D (Pubitemid 41058238)
37. D Pouessel S Culine 2008 High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor Eur Urol 53 2 376 381 17825982 10.1016/j.eururo.2007.08.053 1:CAS:528: DC%2BD1cXislCnsrg%3D (Pubitemid 350296582)
38. CW Pugh PJ Ratcliffe 2003 Regulation of angiogenesis by hypoxia: role of the HIF system Nat Med 9 6 677 684 12778166 10.1038/nm0603-677 1:CAS:528:DC%2BD3sXktFOnur8%3D (Pubitemid 36749216)
39. M Raftopoulou A Hall 2004 Cell migration: Rho GTPases lead the way Dev Biol 265 1 23 32 14697350 10.1016/j.ydbio.2003.06.003 1:CAS:528: DC%2BD3sXhtVShsr%2FJ (Pubitemid 38018819)
40. V Ranpura S Hapani S Wu 2011 Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis JAMA 305 5 487 494 21285426 10.1001/jama.2011.51 1:CAS:528:DC%2BC3MXhs1Chsbs%3D
41. S Rousseau F Houle J Landry J Huot 1997 p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells Oncogene 15 18 2169 2177 9393975 10.1038/sj.onc.1201380 1:CAS:528:DyaK2sXnsFajsrs%3D (Pubitemid 27493906)
42. FA Scappaticci JR Skillings SN Holden HP Gerber K Miller F Kabbinavar, et al. 2007 Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab J Natl Cancer Inst 99 16 1232 1239 17686822 10.1093/jnci/djm086 (Pubitemid 47299901)
43. JS Sebolt-Leopold R Herrera 2004 Targeting the mitogen-activated protein kinase cascade to treat cancer Nat Rev Cancer 4 12 937 947 15573115 10.1038/nrc1503 1:CAS:528:DC%2BD2cXhtVarsLjO (Pubitemid 39626217)
44. N Skuli L Liu A Runge T Wang L Yuan S Patel, et al. 2009 Endothelial deletion of hypoxia-inducible factor-2alpha (HIF-2alpha) alters vascular function and tumor angiogenesis Blood 114 2 469 477 19439736 10.1182/blood-2008-12-193581 1:CAS:528:DC%2BD1MXovVKls7s%3D
45. N Tang L Wang J Esko FJ Giordano Y Huang HP Gerber, et al. 2004 Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis Cancer Cell 6 5 485 495 15542432 10.1016/j.ccr.2004.09.026 1:CAS:528:DC%2BD2cXhtVGlurjN (Pubitemid 39469984)
46. CC Wu FN Ko SC Kuo FY Lee CM Teng 1995 YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase Br J Pharmacol 116 3 1973 1978 8640334 1:CAS:528:DyaK2MXos1Shsrw%3D
47. WL Yeh DY Lu CJ Lin HC Liou WM Fu 2007 Inhibition of hypoxia-induced increase of blood-brain barrier permeability by YC-1 through the antagonism of HIF-1alpha accumulation and VEGF expression Mol Pharmacol 72 2 440 449 17513385 10.1124/mol.107.036418 1:CAS:528:DC%2BD2sXosVKrt78%3D (Pubitemid 47124124)